title: Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib.
abstract: Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumorigenesis of thyroid cancers has led to development of new targeted agents for the management of advanced and refractory disease. Multikinase inhibitors that are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer have been the most widely studied. After an international effort to identify and recruit sufficient patients, four placebo-controlled studies of multikinase inhibitors have been completed. These trials have led to the approval of the first agents with activity in advanced medullary thyroid cancers, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future. The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.
authors.affiliation: Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Neda
authors.initials: N
authors.lastname: Stjepanovic
authors.affiliation: Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Jaume
authors.initials: J
authors.lastname: Capdevila
keywords: lenvatinib; multikinase inhibitors; targeted therapies; thyroid cancer; tyrosine kinase inhibitors
references.citation: Biomed Pharmacother. 2008 Oct;62(8):559-63
references.pmid: 18725177
references.citation: Mol Cancer Res. 2010 Nov;8(11):1439-52
references.pmid: 21047773
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4708-13
references.pmid: 18541897
references.citation: J Clin Oncol. 2009 Apr 1;27(10):1675-84
references.pmid: 19255327
references.citation: J Endocrinol. 1999 Apr;161(1):41-9
references.pmid: 10194527
references.citation: J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
references.pmid: 16684830
references.citation: Am J Pathol. 1999 Dec;155(6):1967-76
references.pmid: 10595926
references.citation: Mol Cell Endocrinol. 2010 May 28;321(1):20-8
references.pmid: 19897009
references.citation: Lancet Oncol. 2010 Oct;11(10):962-72
references.pmid: 20851682
references.citation: J Clin Oncol. 2009 Aug 10;27(23):3794-801
references.pmid: 19564535
references.citation: Eur J Endocrinol. 2009 Dec;161(6):923-31
references.pmid: 19773371
references.citation: Biochem J. 2011 Jul 15;437(2):199-213
references.pmid: 21711248
references.citation: J Clin Oncol. 2010 Feb 10;28(5):767-72
references.pmid: 20065189
references.citation: J Thyroid Res. 2012;2012:847108
references.pmid: 22848860
references.citation: World J Surg. 2000 Aug;24(8):923-33
references.pmid: 10865036
references.citation: Cancer. 2009 Aug 15;115(16):3801-7
references.pmid: 19598221
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5260-8
references.pmid: 20847059
references.citation: J Cancer Epidemiol. 2013;2013:965212
references.pmid: 23737785
references.citation: Science. 2000 Aug 25;289(5483):1357-60
references.pmid: 10958784
references.citation: Cancer Discov. 2013 Mar;3(3):264-79
references.pmid: 23418312
references.citation: Exp Cell Res. 2003 Mar 10;284(1):99-110
references.pmid: 12648469
references.citation: Nature. 1993 Jun 3;363(6428):458-60
references.pmid: 8099202
references.citation: J Clin Oncol. 2012 Jan 10;30(2):134-41
references.pmid: 22025146
references.citation: Expert Rev Mol Diagn. 2008 Jan;8(1):83-95
references.pmid: 18088233
references.citation: Science. 1991 Feb 15;251(4995):802-4
references.pmid: 1846706
references.citation: J Clin Endocrinol Metab. 1995 Mar;80(3):1006-11
references.pmid: 7533768
references.citation: J Clin Oncol. 2010 May 10;28(14):2323-30
references.pmid: 20368568
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2660-6
references.pmid: 21606412
references.citation: Eur J Endocrinol. 2011 Aug;165(2):315-22
references.pmid: 21566072
references.citation: Nat Rev Cancer. 2008 Aug;8(8):592-603
references.pmid: 18650835
references.citation: J Clin Oncol. 2013 Oct 10;31(29):3639-46
references.pmid: 24002501
references.citation: Lancet Oncol. 2012 Sep;13(9):897-905
references.pmid: 22898678
references.citation: Endocr Relat Cancer. 2012 Apr 10;19(2):209-16
references.pmid: 22285864
references.citation: J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71
references.pmid: 20371662
references.citation: N Engl J Med. 2005 Jul 14;353(2):172-87
references.pmid: 16014887
references.citation: Cancer Res. 2009 Jun 1;69(11):4885-93
references.pmid: 19487299
references.citation: Cell Cycle. 2007 Feb 1;6(3):377-9
references.pmid: 17297294
references.citation: Eur J Cancer. 2002 Sep;38 Suppl 5:S3-10
references.pmid: 12528767
references.citation: N Engl J Med. 2008 May 8;358(19):2039-49
references.pmid: 18463380
references.citation: Cancer Res. 2006 Sep 1;66(17):8715-21
references.pmid: 16951187
references.citation: J Clin Endocrinol Metab. 2012 Sep;97(9):3179-84
references.pmid: 22774206
references.citation: Endocr Relat Cancer. 2010 Jan 29;17(1):7-16
references.pmid: 19776290
references.citation: N Engl J Med. 2008 Jul 3;359(1):31-42
references.pmid: 18596272
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5459-65
references.pmid: 18765537
references.citation: Endocrinology. 2005 Mar;146(3):1145-53
references.pmid: 15564323
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4714-9
references.pmid: 18541894
references.citation: Br J Cancer. 2012 May 8;106(10):1598-604
references.pmid: 22516948
references.citation: Clin Oncol (R Coll Radiol). 2010 Aug;22(6):464-8
references.pmid: 20452757
references.citation: Clin Cancer Res. 2016 Jan 1;22(1):44-53
references.pmid: 26311725
references.citation: J Clin Endocrinol Metab. 2006 Jan;91(1):313-9
references.pmid: 16263822
references.citation: Mod Pathol. 2008 May;21 Suppl 2:S37-43
references.pmid: 18437172